WebAug 16, 2024 · Opthea previously announced positive results of improvements in visual acuity (VA) and retinal swelling (central subfield thickness and sub-retinal fluid) in the Phase 1/2a study patients that included treatment naïve and prior-treated patients receiving OPT-302 + Lucentis® combination therapy. WebMar 15, 2024 · Opthea (ASX:OPT; Nasdaq: OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including...
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
WebMar 15, 2024 · --Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to … WebJan 7, 2024 · MELBOURNE, Australia, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient recruitment into the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with … literary genres poster
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 ... - Eyewire+
WebMar 30, 2024 · Opthea has also reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 … WebFeb 17, 2024 · OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe) The safety and scientific validity of this study is the responsibility of the … WebJul 23, 2024 · Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A. Opthea has also reported outcomes from an international, multi-centre, prospective, sham-controlled,... literary genres of the earlier periods